Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- OA-Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction
Final published version, 854 KB, PDF document
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.
Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction
Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
Original language | English |
---|---|
Journal | European Journal of Heart Failure |
Volume | 22 |
Issue number | 11 |
Pages (from-to) | 2160-2171 |
ISSN | 1388-9842 |
DOIs | |
Publication status | Published - 2020 |
- Heart failure, Omecamtiv mecarbil, Cardiac myosin activator, Inotrope, Myotrope, Cardiovascular outcomes trial, CARDIAC MYOSIN ACTIVATOR, INCREASE CONTRACTILITY, TOLVAPTAN, MORTALITY, OUTCOMES, PHASE-2, WOMEN
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 251577468